quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:17:31·44d
SECFiling
Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

PRLD· Prelude Therapeutics Incorporated
Health Care
Original source

Companies

  • PRLD
    Prelude Therapeutics Incorporated
    Health Care

Recent analyst ratings

  • Sep 19UpdateH.C. Wainwright$5.00
  • Jun 20UpdateBarclays$3.00
  • Mar 13UpdateJMP Securities$7.00
  • Feb 20UpdateH.C. Wainwright$5.00
  • Dec 19UpdateMorgan Stanley$4.00
  • Nov 21UpdateBofA Securities$6.00

Related

  • SEC5h
    Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated
  • INSIDER7h
    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)
  • INSIDER7h
    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)
  • SEC1d
    Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated
  • INSIDER1d
    SEC Form 4 filed by Baker Bros. Advisors Lp
  • SEC3d
    SEC Form 8-K filed by Prelude Therapeutics Incorporated
  • SEC3d
    SEC Form 424B5 filed by Prelude Therapeutics Incorporated
  • PR3d
    Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022